{"id":626962,"date":"2022-11-23T17:42:01","date_gmt":"2022-11-23T17:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=626962"},"modified":"2022-11-23T17:42:01","modified_gmt":"2022-11-23T17:42:01","slug":"hemophilia-b-market-to-register-incremental-growth-during-the-forecast-period-201932-asserts-delveinsight-key-companies-csl-behringuniqure-hemgenix-apcintex-sangamo-spark-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hemophilia-b-market-to-register-incremental-growth-during-the-forecast-period-201932-asserts-delveinsight-key-companies-csl-behringuniqure-hemgenix-apcintex-sangamo-spark-therapeutics_626962.html","title":{"rendered":"Hemophilia B Market to Register Incremental Growth During the Forecast Period (2019-32), Asserts DelveInsight | Key Companies – CSL Behring\/uniQure (Hemgenix), ApcinteX, Sangamo, Spark Therapeutics"},"content":{"rendered":"
\n
\"Hemophilia<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Hemophilia B market dynamics are anticipated to change in the coming years owing to the advancement in the diagnosis methodologies, improvement in the half-life of products, raising awareness of the diseases, incremental healthcare spending across the world and the expected launch of emerging therapies.<\/div>\n

Companies across the globe are working towards the development of novel treatment therapies for Hemophilia B. Additionally, some of the major pharma and biotech giants have also recently shifted their focus toward this indication.<\/em><\/p>\n

DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hemophilia B market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Hemophilia B market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Hemophilia<\/p>\n

Hemophilia B: An Overview<\/strong><\/p>\n

According to the Centers for Disease Control and Prevention, Hemophilia B is a genetic disorder caused by missing or defective Factor IX clotting protein. With the lack of this, the blood cannot clot properly to control bleeding like haemophilia A, it is also inherited and is caused by a spontaneous genetic mutation in one-third of the cases. Individuals with Hemophilia B do not bleed faster than unaffected individuals; they bleed longer.<\/p>\n

Hemophilia B Market Key Facts<\/strong><\/p>\n